Skip to main content

Table 1 all of the ncRNAs associated with chemotherapeutic resistance in BCa

From: Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells

Study

Year

Gene

Country

Drug

Results

Chen [17]

2020

MST1P2, miR-133b

China

Cisplatin

MST1P2/miR-133b axis had an important role in cisplatin-resistance of bladder cancer through SIRT1/p53 pathway.

Chen [18]

2019

HIF1A-AS2

China

Cisplatin

HIF1A-AS2 enhances survival of tumor cells by upregulating HMGA1.

Wu [19]

2019

UCA1

China

Rapamycin

UCA1 acts as an endogenous sponge to down regulate the miR-582-5p which resulted in ATG7 over expression.

Zhang [20]

2017

GAS5

China

Doxorubicin

GAS5 increased doxorubicin-induced apoptosis through BCL-2 suppression.

Liu [21]

2019

MALAT1

China

Cisplatin

MALAT1 induced chemo resistance through regulating miR-101-3p/VEGFC axis.

Li [22]

2019

GHET1

China

Gemcitabine

GHET1 up regulated the MRP1.

An [23]

2018

FOXD2-AS1

China

Gemcitabine

FOXD2-AS1 indirectly targets the ABCC3 through miR-143 sponging.

Wang [24]

2017

MiR-143

China

Gemcitabine

The miR-143 attenuated gemcitabine resistance via IGF-1R suppression.

Fan [25]

2014

UCA1

China

Cisplatin

UCA1 overexpression was contributed to upregulation of WNT6.

Pan [26]

2016

UCA1

China

Cisplatin, Gemcitabine

UCA1 activates miR-196a-5p via CREB which results in gemcitabine/cisplatin resistance.

Xie [27]

2017

TUG1

China

Doxorubicin

TUG1 knockdown decreased Dox resistance through restraining the activity of Wnt/β-catenin pathway.

Xie [28]

2018

CDKN2B-AS

China

Gemcitabine

CDKN2B-AS induced Gemcitabine-resistance via sponging Let-7.

Zhuang [29]

2017

LET

China

Gemcitabine

TGFβ1 promotes gemcitabine resistance through LncRNA-LET/NF90/miR-145 axis.

Li [30]

2019

DLEU1

China

Cisplatin

DLEU1 up regulated the HS3ST3B1 via miR-99b suppression.

Zhao [31]

2019

NEAT1.1

China

Cisplatin

NEAT1.1 was down regulated following cisplatin treatment.

Xiao [32]

2018

MiR-22-3p

China

Paclitaxel, Adriamycin, Epirubicin, hydroxycamptothecin, Cisplatin, and Gemcitabine

MiR-22-3p enhanced resistance to chemotherapy in bladder tumor cells through suppressing NET1.

Deng [33]

2015

MiR-27a

China

Paclitaxel, Adriamycin, Cisplatin

MiR-27a/RUNX-1 pathway has a key function in chemo-resistance.

Drayton [34]

2014

MiR-27a

UK

Cisplatin

MiR-27a deregulation induced cisplatin resistance in bladder cancer cells via up regulating SLC7A11.

Bu [35]

2014

MiR-101

China

Cisplatin

MiR-101 regulates cisplatin sensitivity in bladder tumor cell lines via targeting the COX-2.

Vinall [36]

2012

MiR-34a

USA

Cisplatin

MiR-34a sensitized tumor cells to cisplatin by targeting SIRT-1 and CDK6.

Li [37]

2014

MiR-34a

China

Cisplatin

MiR-34a targets CD44 after cisplatin therapy.

Liu [38]

2018

MiR-34a

China

Epirubicin

MiR-34a significantly reduced Epirubicin chemo resistance in bladder tumor cells through targeting TCF1 and LEF1.

Zhang [39]

2017

MiR-34a

China

Cisplatin, Gemcitabine

MiR34a regulation of GOLPH3 is active in bladder CSCs resistant to gemcitabine and cisplatin.

Tan [40]

2019

MiR-34b-3p

China

Paclitaxel, Adriamycin, Epirubicin, Cisplatin, Pirarubicin

MiR-34b-3p attenuated chemo resistance in bladder cancer through suppressing CCND2 and P2RY1.

Luan [41]

2018

MiR-98

China

Cisplatin, Doxorubicin

MiR-98 promotes chemo-resistance through targeting LASS2.

Li [42]

2019

MiR-101-3p

China

Cisplatin

MiR-101-3p decreased cisplatin-resistance in bladder urothelial carcinoma through repressing EZH2 and MRP1.

Cao [43]

2018

MiR-129-5p

China

Gemcitabine

MiR-129-5p inhibits resistance to gemcitabine in bladder cancer cells and promotes their apoptosis via targeting WNT5a.

Lv [44]

2015

MiR-193a-3p

China

Pirarubicin, Paclitaxel,

Adriamycin,

Epirubicin Hydrochloride, and Cisplatin

MiR-193a-3p mediated HOXC9 down regulation which resulted in poorer sensitivity to chemotherapeutic drugs.

Deng [45]

2015

MiR-193a-3p

China

Pirarubicin, Paclitaxel, Adriamycin, Epirubicin hydrochloride, and Cisplatin

PSEN1 was directly targeted by miR-193a-3p and executed its impact on the multi-chemo resistance.

Lin [46]

2017

MiR-193b-3p

Taiwan

Cisplatin

CEBPD/miR-193b-3p axis had key roles in cisplatin response.

Deng [47]

2014

MiR-193a-3p

China

Paclitaxel, Adriamycin, Epirubicin Hydrochloride, and Cisplatin

MiR-193a-3p induced multi-drug resistance in bladder cancer cells through down regulating LOXL4.

Lv [48]

2014

MiR-193a-3p

China

Pirarubicin hydrochloride, Paclitaxel, Adriamycin, and Epirubicin hydrochloride

HIC2, SRSF2, and PLAU achieve their role in relaying miR-193a-3p’s effect on chemo resistance in bladder cancer through regulation of Myc/Max, NF-jB, DNA damage response, and NOTCH pathway.

Shindo [49]

2018

MiR-200b

Japan

Cisplatin

TNFSF10, ICAM1, and IGFBP3 were induced in the resistant cells as a result of miR-200b + cisplatin treatment.

Zhang [50]

2015

MiR-203

China

Cisplatin

The miR-203 up regulation increased the cytotoxic effects of cisplatin and decreased tumor cell viability through suppressing Survivin and BCL-w.

Liu [51]

2018

MiR-214

China

Cisplatin

MiR-214 decreased chemo resistance in bladder cancer tissues and cell lines by suppressing NTN1.

Li [52]

2017

MiR-218

China

Cisplatin

MiR-218 up regulation reduced cisplatin resistance through GLUT1 targeting.

Zeng [53]

2016

MiR-222

China

Cisplatin

MiR-222 up regulation decreased cisplatin-induced apoptosis in bladder tumor cells through modulation of PPP2R2A/Akt/mTOR pathway.